Risankizumab: Daily Practice Experience of High Need Patients

Risankizumab: Daily Practice Experience of High Need Patients

Psoriasis is a chronic inflammatory disease which affects 29.5 million people worldwide and it can negatively impact quality of life, especially when it affects a special localization, such as nails, face, palms and soles, or intertriginous regions. Risankizumab is a humanized monoclonal antibody wh...

Full description

Bibliographic Details
Main Authors: Alexandra M. G. Brunasso, Martina Burlando, Fabrizio Amoruso, Luisa Arancio, Giovanna Malara, Raffaella Manzo, Maria Antonia Montesu, Giacomo Caldarola
Format: Article
Language:English
Published: MDPI AG 2023-06-01
Series:Biomedicines
Subjects:
psoriasis
risankizumab
monoclonal antibody
Online Access:https://www.mdpi.com/2227-9059/11/6/1769

Internet

https://www.mdpi.com/2227-9059/11/6/1769

Similar Items